Mirum Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Mirum Pharmaceuticals
MIRM Stock  USD 103.47  0.25  0.24%   
Mirum Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Mirum Pharmaceuticals' valuation are provided below:
Gross Profit
377 M
Profit Margin
(0.09)
Market Capitalization
6.2 B
Enterprise Value Revenue
12.9422
Revenue
471.8 M
There are over one hundred nineteen available fundamental ratios for Mirum Pharmaceuticals, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to check Mirum Pharmaceuticals' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 2nd of February 2026, Market Cap is likely to grow to about 1.1 B. Also, Enterprise Value is likely to grow to about 1.2 B

Mirum Pharmaceuticals Total Revenue

406.79 Million

Check Mirum Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mirum Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 16.7 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 28.5 M, as well as many indicators such as Price To Sales Ratio of 12.69, Dividend Yield of 0.0 or PTB Ratio of 8.23. Mirum financial statements analysis is a perfect complement when working with Mirum Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Mirum Stock
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

Mirum Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets809.9 M771.4 M258.9 M
Slightly volatile
Other Current Liabilities133.1 M126.8 M34.1 M
Slightly volatile
Total Current Liabilities152.8 M145.5 M39.6 M
Slightly volatile
Other Liabilities174.9 M166.6 M59.8 M
Slightly volatile
Accounts Payable17.7 M16.8 M4.9 M
Slightly volatile
Cash268.7 M255.9 M100.8 M
Slightly volatile
Cash And Short Term Investments200.4 M322.4 M130.2 M
Slightly volatile
Common Stock Total Equity3.4 K3.6 K3.7 M
Slightly volatile
Common Stock Shares Outstanding35.2 M54.7 M29.3 M
Slightly volatile
Liabilities And Stockholders Equity809.9 M771.4 M258.9 M
Slightly volatile
Non Current Liabilities Total384.7 M366.3 M132.4 M
Slightly volatile
Capital Surpluse320.7 M615.3 M203.8 M
Slightly volatile
Other Current Assets6.9 M13.6 M3.8 M
Slightly volatile
Other Stockholder Equity513.1 M1 B344 M
Slightly volatile
Total Liabilities537.5 M511.9 M172 M
Slightly volatile
Total Current Assets242.8 M451.7 M156.2 M
Slightly volatile
Capital Stock4.3 K4.5 K3.7 M
Slightly volatile
Net Working Capital187 M306.2 M122.3 M
Slightly volatile
Common Stock4.3 K4.5 K3.7 M
Slightly volatile
Short and Long Term Debt Total383.7 M365.4 M83.5 M
Slightly volatile
Property Plant And Equipment Net11.9 M11.3 M4.7 M
Slightly volatile

Mirum Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income16.7 M15.9 M3.9 M
Slightly volatile
Depreciation And Amortization28.5 M27.2 M7.9 M
Slightly volatile
Selling General Administrative230.3 M219.3 M52.3 M
Slightly volatile
Selling And Marketing Expenses21.9 M13.2 M9.1 M
Slightly volatile
Other Operating Expenses512.6 M488.2 M135.7 M
Slightly volatile
Research Development95.6 M161.7 M52 M
Slightly volatile
Total Operating Expenses414 M394.3 M115.9 M
Slightly volatile
Reconciled Depreciation28.5 M27.2 M5.6 M
Slightly volatile

Mirum Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock13.3 M14 M51.8 M
Slightly volatile
Stock Based Compensation58.5 M55.7 M15.7 M
Slightly volatile
Depreciation28.5 M27.2 M5.8 M
Slightly volatile
Capital Expenditures1.1 M1.1 M6.5 M
Pretty Stable
Total Cash From Financing Activities19.3 M20.4 M83.7 M
Pretty Stable
End Period Cash Flow153.2 M256.4 M105.9 M
Slightly volatile
Change To Netincome19.8 M31.1 M21.7 M
Pretty Stable
Change To Liabilities10.5 M8.8 M6.6 M
Slightly volatile
Begin Period Cash Flow345.7 M329.3 M111.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.696.7120.2071
Slightly volatile
Days Sales Outstanding78.7876.3472.6114
Slightly volatile
Stock Based Compensation To Revenue0.160.170.9111
Slightly volatile
Capex To Depreciation0.04590.04831.8009
Pretty Stable
EV To Sales12.37.0319.1473
Slightly volatile
Inventory Turnover1.853.281.6588
Slightly volatile
Days Of Inventory On Hand200115249
Slightly volatile
Payables Turnover5.285.031.4726
Slightly volatile
Sales General And Administrative To Revenue0.620.652.041
Slightly volatile
Research And Ddevelopement To Revenue0.460.485.0414
Slightly volatile
Capex To Revenue0.00320.00340.7088
Slightly volatile
Cash Per Share4.465.313.9362
Slightly volatile
Days Payables Outstanding71.475.162.5 K
Slightly volatile
Intangibles To Total Assets0.20.340.1314
Slightly volatile
Current Ratio3.393.5713.7825
Slightly volatile
Receivables Turnover4.434.955.2902
Slightly volatile
Debt To Equity1.331.270.3284
Slightly volatile
Capex Per Share0.01790.01880.2437
Slightly volatile
Revenue Per Share6.76.382.034
Slightly volatile
Interest Debt Per Share6.66.291.8068
Slightly volatile
Debt To Assets0.450.430.124
Slightly volatile
Operating Cycle308213325
Slightly volatile
Days Of Payables Outstanding71.475.162.5 K
Slightly volatile
Ebt Per Ebit1.881.143.68
Slightly volatile
Long Term Debt To Capitalization0.450.520.5456
Slightly volatile
Total Debt To Capitalization0.550.530.1497
Slightly volatile
Debt Equity Ratio1.331.270.3284
Slightly volatile
Quick Ratio3.23.3713.7269
Slightly volatile
Net Income Per E B T0.80.910.9816
Slightly volatile
Cash Ratio1.922.0212.337
Slightly volatile
Days Of Inventory Outstanding200115249
Slightly volatile
Days Of Sales Outstanding78.7876.3472.6114
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.991.0411.6669
Slightly volatile
Fixed Asset Turnover33.6730.8918.5568
Slightly volatile
Debt Ratio0.450.430.124
Slightly volatile
Price Sales Ratio12.696.7120.2071
Slightly volatile
Asset Turnover0.470.450.1593
Slightly volatile
Gross Profit Margin0.890.870.8771
Slightly volatile

Mirum Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.1 B1.1 B592.3 M
Slightly volatile
Enterprise Value1.2 B1.1 B560.7 M
Slightly volatile

Mirum Fundamental Market Drivers

Forward Price Earnings39.6825
Cash And Short Term Investments280.3 M

Mirum Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Mirum Pharmaceuticals Financial Statements

Mirum Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Mirum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-993.6 K-943.9 K
Total Revenue387.4 M406.8 M
Cost Of Revenue93.9 M98.6 M
Stock Based Compensation To Revenue 0.17  0.16 
Sales General And Administrative To Revenue 0.65  0.62 
Research And Ddevelopement To Revenue 0.48  0.46 
Revenue Per Share 6.38  6.70 
Ebit Per Revenue(0.23)(0.25)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:
How To Invest In Mirum
Details
Is Mirum Stock a good investment?
Details
What is Mirum Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could Mirum diversify its offerings? Factors like these will boost the valuation of Mirum Pharmaceuticals. Expected growth trajectory for Mirum significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mirum Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.85)
Revenue Per Share
9.559
Quarterly Revenue Growth
0.472
Return On Assets
(0.04)
Return On Equity
(0.16)
Understanding Mirum Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Mirum's accounting equity. The concept of intrinsic value—what Mirum Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Mirum Pharmaceuticals' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Mirum Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mirum Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Mirum Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY